Pat Heckman, DO

PGY-5 Heme/Onc Fellow @UKMarkey

[Markey Cancer Center @UKMarkey]

Congratulations to our graduating @UKHemOnc
fellows! We are excited that @chahine_zena will continue in Hematology @UKMarkey. @BaraAlzghoulMd will join St. Claire Medical Center and @aejohn02 @pmcpikeville.
@IndyOncDoc in Indiana; Dr. Dhahri in Washington, DC! Congratulations!

[UK HemOnc Fellows @UKHemOnc]

Hail the new chiefs! @MCCTrainees @UKMarkey @Reema_PatelMD @aejohn02 @IndyOncDoc @HemOncFellows @universityofky @ReshmaRamlal2 @SusanneArnoldMD

[UK HemOnc Fellows @UKHemOnc]

Fellowship life is busy and we don’t always have time for fun. When we do we do it only with Joe’s original Kansas City barbecue sauce! @HemOncFellows @MCCTrainees @UKMarkey @BaraAlzghoulMd @chahine_zena @GG_ONCMD @rinayadav188 @aejohn02 @IndyOncDoc @Reema_PatelMD @AymanQasrawi

[Pat Heckman, DO @IndyOncDoc]

Curious how these results would affect our our abstract “Oncologists’ Perspectives on mHSPC Management” #GU23

[Pat Heckman, DO @IndyOncDoc]

Updated #ARASENS results show OS benefit w/ triplet therapy (ADT + Docetaxel x6C + Darolutamide) regardless of volume/risk stratification. *Large % are de novo #GU23

[Pat Heckman, DO @IndyOncDoc]

Starting off the morning at #GU23 with PARPi in mCRPC

[Pat Heckman, DO @IndyOncDoc]

Enjoyed listening to @neerajaiims, @TDorffOnc, and @DrRanaMcKay discuss the (near) future in prostate cancer management. As a trainee, the abundance of therapies can be intimidating but that pales in comparison to the invigorating hope I have for our patients! #GU23

[Pat Heckman, DO @IndyOncDoc]

@BaraAlzghoulMd @chahine_zena @aejohn02

[Pat Heckman, DO @IndyOncDoc]

Journal club today! Talking adagrasib + cetuximab in KRAS G12C mutated mCRC - ORR 46% / mPFS 6.9mo … not a silver bullet but maybe the start of meaningful targeted responses in mCRC - esp. for an “undruggable” & prevalent mutation